Boehringer Ingelheim secured accelerated FDA approval for Hernexeos (zongertinib), the first oral HER2-targeted treatment for advanced non-small cell lung cancer (NSCLC) harboring activating HER2 mutations. Designed for patients with unresectable tumors or those previously treated, Hernexeos competes with AstraZeneca's Enhertu antibody-drug conjugate. The approval marks a pivotal advancement in targeted lung cancer therapy, offering an oral alternative. Additionally, Thermo Fisher received FDA clearance for its Oncomine Dx Target Test as a companion diagnostic to identify appropriate candidates for Hernexeos treatment, enhancing precision medicine in NSCLC.